These weaknesses have practical clinical implications: in metastatic disease, reliance on PD-L1 to determine eligibility for immunotherapy may exclude some patients who could benefit, while in early TNBC the proven efficacy of immunotherapy regardless of PD-L1 status makes such selection criteria questionable. This evidence concerns the gene CD274 and metastatic neoplasm.